Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D., Lyra’s President and Chief Executive Officer, will present in a virtual format at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be made available for on-demand viewing on Monday, September 13, 2021 at 7:00 a.m. ET.

A webcast of the virtual presentation will be available in the Investor Relations section of the Company’s website at https://investors.lyratherapeutics.com. The webcast replay will be available for 90 days following the event.

About Lyra Therapeutics

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches. Lyra’s XTreo™ platform is comprised of a biocompatible mesh scaffold, an engineered elastomeric matrix and a versatile polymer-drug complex. The company’s current pipeline of therapeutics target tissues deep in the ear, nose and throat passages and are designed to deliver continuous drug therapy for months following a single non-invasive, in-office administration. Lyra’s lead product candidate, LYR-210, is entering Phase 3 clinical development for the treatment of chronic rhinosinusitis as an alternative to primary sinus surgery. Lyra’s second product candidate, LYR-220 which is entering Phase 2 development, is designed to be a potential preferred alternative to revision sinus surgery and post-surgical medical management. Both product candidates are designed to deliver up to six months of continuous anti-inflammatory drug therapy with a single treatment. For more information, please visit lyratherapeutics.com and follow us on LinkedIn and Twitter.